35 related articles for article (PubMed ID: 16875815)
1. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface.
Gerspach J; Németh J; Münkel S; Wajant H; Pfizenmaier K
Cancer Immunol Immunother; 2006 Dec; 55(12):1590-600. PubMed ID: 16636812
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy.
Cheng Z; Huang Y; Shao P; Wang L; Zhu S; Yu J; Lu W
ACS Omega; 2022 Jan; 7(1):1082-1089. PubMed ID: 35036771
[TBL] [Abstract][Full Text] [Related]
3. Ab locks for improving the selectivity and safety of antibody drugs.
Lin WW; Lu YC; Chuang CH; Cheng TL
J Biomed Sci; 2020 Jun; 27(1):76. PubMed ID: 32586313
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.
Kwiatkowska A; Couture F; Ait-Mohand S; Desjardins R; Dory YL; Guérin B; Day R
Sci Rep; 2019 Feb; 9(1):2118. PubMed ID: 30765725
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-controlled tumor penetrating peptide.
Braun GB; Sugahara KN; Yu OM; Kotamraju VR; Mölder T; Lowy AM; Ruoslahti E; Teesalu T
J Control Release; 2016 Jun; 232():188-95. PubMed ID: 27106816
[TBL] [Abstract][Full Text] [Related]
6. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.
Liu Z; Chen X
Chem Soc Rev; 2016 Mar; 45(5):1432-56. PubMed ID: 26771036
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.
Elsadek B; Graeser R; Warnecke A; Unger C; Saleem T; El-Melegy N; Madkor H; Kratz F
ACS Med Chem Lett; 2010 Aug; 1(5):234-8. PubMed ID: 24900200
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
Metz S; Panke C; Haas AK; Schanzer J; Lau W; Croasdale R; Hoffmann E; Schneider B; Auer J; Gassner C; Bossenmaier B; Umana P; Sustmann C; Brinkmann U
Protein Eng Des Sel; 2012 Oct; 25(10):571-80. PubMed ID: 22976197
[TBL] [Abstract][Full Text] [Related]
9. Protease-activated drug development.
Choi KY; Swierczewska M; Lee S; Chen X
Theranostics; 2012; 2(2):156-78. PubMed ID: 22400063
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
11. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Chung DE; Kratz F
Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
[TBL] [Abstract][Full Text] [Related]
13. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
14. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
